Opportunity Information: Apply for RFA DK 11 024
Apply for RFA DK 11 024
- The National Institutes of Health in the food and nutrition health income security and social services sector is offering a public funding opportunity titled "Small Business Innovation Research to Develop New Methods and Technologies able to Identify Individuals at Risk of Developing Type 1 Diabetes T1D (R43)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research 93.865 Child Health and Human Development Extramural Research.
- This funding opportunity was created on Sep 21, 2011 and posted on Sep 21, 2011.
- Applicants must submit their applications by Dec 22, 2011. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $1,200,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $300,000.00 in funding.
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Small Business Innovation Research to Develop New Methods and Technologies able to Identify Individuals at Risk of Developing Type 1 Diabetes (T1D) (R43)" is a National Institutes of Health (NIH) funding announcement designed to support early-stage, high-impact innovation from small businesses. The core purpose of the program is to fund research and development efforts that lead to new or improved technologies for identifying people who are at elevated risk of developing type 1 diabetes and for monitoring those individuals over time. In practical terms, the announcement is focused on strengthening the tools available for early detection and follow-up, which are both central to improving prevention research, timely intervention strategies, and the overall understanding of how type 1 diabetes develops before clinical diagnosis.
This opportunity is structured under the Small Business Innovation Research (SBIR) program mechanism, specifically the R43 funding instrument, which generally corresponds to an SBIR Phase I award. Phase I SBIR projects usually emphasize feasibility, proof-of-concept, and early technical validation, meaning applicants are expected to show that their scientific approach is sound and that the underlying technology can realistically be developed into something that works in real-world settings. The emphasis on innovative technologies suggests NIH is seeking approaches that go beyond incremental refinements and instead offer meaningful advances, such as better performance, easier deployment, reduced cost, improved scalability, or the ability to generate clinically useful risk information earlier than existing methods.
Only small business concerns are eligible to apply, reflecting the SBIR program's goal of translating ideas into usable products and services through the agility and commercialization focus of the small business sector. There is no cost-sharing or matching requirement, so applicants are not required to contribute additional funds as a condition of receiving the award. The program falls under NIH and is associated with the broader federal assistance listings for extramural research in diabetes, digestive and kidney diseases (CFDA 93.847) and child health and human development (CFDA 93.865), which aligns with the reality that type 1 diabetes risk identification often involves pediatric and adolescent populations as well as family-based risk assessment and long-term monitoring.
From a funding perspective, the announcement lists an estimated total funding amount of $1,200,000, with an award ceiling of $300,000. That ceiling indicates the maximum budget level NIH expects to support per award under this solicitation, which is typical of Phase I SBIR budgets intended to demonstrate early feasibility rather than to fund large clinical studies. The opportunity was posted on September 21, 2011, with an original and current closing date of December 22, 2011, and it was later archived on January 22, 2012. While the dates indicate this specific solicitation is historical, the content reflects an ongoing NIH priority area: improving the ability to detect risk for type 1 diabetes before onset and to track progression in individuals who may be in pre-symptomatic stages.
The underlying public health and research rationale is that type 1 diabetes often develops over a period of time, with measurable biological changes that can precede symptomatic disease. Better tools for identifying at-risk individuals can strengthen screening strategies, enable closer follow-up, and support enrollment into prevention or delay trials. Technologies supported under a program like this could plausibly include novel assays, biomarkers, device-based screening tools, improved analytic methods, or integrated platforms that make risk detection more accurate and more practical for broader use. The announcement language is intentionally broad, which is typical for technology-development FOAs, because NIH is often trying to attract a wide range of creative approaches from diagnostics developers, biomedical device companies, digital health startups, and other small businesses capable of translating research into products.
Administrative and support information is also provided through NIH. The announcement includes a link to the full FOA details hosted on the NIH grants site (http://grants.nih.gov/grants/guide/rfa_files/RFA-DK-11-024.html). For access issues or technical problems with the posting, the listed point of contact is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV. This reflects that the provided contact is primarily for difficulties accessing the announcement online rather than for scientific or programmatic questions about the research topic itself.
In short, this SBIR R43 opportunity was a targeted NIH effort to push forward early-stage, small business-led R&D aimed at creating or improving methods and technologies for early identification and longitudinal follow-up of individuals at risk for type 1 diabetes. The funding levels and eligibility criteria are aligned with feasibility-stage innovation, with the broader goal of accelerating practical tools that can support prevention research and earlier clinical action in populations at risk.
FAQs: SBIR (R43) - New Methods/Technologies to Identify Individuals at Risk of Type 1 Diabetes (T1D)
What is the title of this grant opportunity?
The opportunity is titled "Small Business Innovation Research to Develop New Methods and Technologies able to Identify Individuals at Risk of Developing Type 1 Diabetes (T1D) (R43)."
Which agency is offering this funding opportunity?
This is a National Institutes of Health (NIH) funding announcement.
What is the main purpose of this funding announcement?
The purpose is to support early-stage, high-impact innovation from small businesses to create new or improved methods and technologies that can identify people at elevated risk of developing type 1 diabetes and monitor those individuals over time.
What types of activities or outcomes is NIH trying to support through this opportunity?
The focus is on research and development that strengthens tools for early detection and follow-up of individuals at risk for T1D. The intended outcome is improved ability to detect risk earlier and track progression prior to clinical diagnosis, supporting prevention research and timely intervention strategies.
What funding mechanism is being used?
The opportunity uses the Small Business Innovation Research (SBIR) program mechanism, specifically the R43 funding instrument, which generally corresponds to an SBIR Phase I award.
What does "SBIR Phase I" generally mean in the context of this opportunity?
Phase I projects typically emphasize feasibility, proof-of-concept, and early technical validation. Applicants are generally expected to show the approach is scientifically sound and that the technology can realistically be developed into something that works in real-world settings.
Who is eligible to apply?
Only small business concerns are eligible to apply, consistent with SBIR program goals of translating innovations into usable products and services through small business-led development.
Is cost-sharing or matching required?
No. The announcement states there is no cost-sharing or matching requirement.
What is the estimated total funding amount for this opportunity?
The announcement lists an estimated total funding amount of $1,200,000.
What is the maximum award amount (award ceiling)?
The award ceiling is $300,000, indicating the maximum budget level NIH expects to support per award under this solicitation.
Why is the award ceiling aligned with Phase I SBIR awards?
The described ceiling is typical for Phase I SBIR budgets that are intended to demonstrate early feasibility rather than support large clinical studies.
What specific problem area is this opportunity trying to address?
It targets the need for better ways to identify individuals who are at elevated risk of developing type 1 diabetes before symptoms appear, and to monitor those individuals longitudinally.
Why is early identification of T1D risk a priority in this announcement?
The rationale described is that type 1 diabetes often develops over time, with measurable biological changes that can occur before symptomatic disease. Better tools could strengthen screening strategies, enable closer follow-up, and support enrollment into prevention or delay trials.
What kinds of technologies might be responsive to this announcement?
The announcement is broadly framed to attract innovative approaches. Examples described or implied include novel assays, biomarkers, device-based screening tools, improved analytic methods, or integrated platforms that make risk detection more accurate and more practical for broader use.
Is this announcement limited to incremental improvements, or does it emphasize bigger advances?
It emphasizes innovative technologies that go beyond incremental refinements and instead offer meaningful advances (for example: better performance, easier deployment, reduced cost, improved scalability, or earlier generation of clinically useful risk information compared to existing methods).
Does the opportunity mention particular populations or contexts relevant to T1D risk identification?
It notes alignment with federal assistance listings related to diabetes and also child health and human development, reflecting that T1D risk identification often involves pediatric and adolescent populations, as well as family-based risk assessment and long-term monitoring.
Which federal assistance listings (CFDA) are associated with this opportunity?
The opportunity is associated with CFDA 93.847 (extramural research in diabetes, digestive and kidney diseases) and CFDA 93.865 (child health and human development).
What are the key dates listed for this opportunity?
It was posted on September 21, 2011. The original and current closing date listed is December 22, 2011. It was archived on January 22, 2012.
Is this specific solicitation still open?
No. Based on the provided dates, this solicitation is historical (it closed on December 22, 2011 and was archived on January 22, 2012).
Where can I find the full funding opportunity announcement (FOA) details?
The full FOA details are available at: http://grants.nih.gov/grants/guide/rfa_files/RFA-DK-11-024.html
Who is the listed contact, and what are they for?
The listed point of contact is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV, and the context provided indicates this contact is for access issues or technical problems with the posting (not for scientific or programmatic questions).
How is this opportunity described in terms of overall intent?
It is described as a targeted NIH effort to push forward early-stage, small business-led R&D aimed at creating or improving methods and technologies for early identification and longitudinal follow-up of individuals at risk for type 1 diabetes.
Browse more business programs for Business Consultants, Innovation Research Organizations, Business Innovation, Diabetes Research
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Food and Nutrition Health Income Security and Social Services
Next opportunity: NIH Directors Transformative Research Awards (R01)
Previous opportunity: Small Business Innovation Research to Develop New Therapeutics and Monitoring Technologies for Type 1 Diabetes (T1D) Towards an Artificial Pancreas (SBIR) (R43/R44)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DK 11 024
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DK 11 024) also looked into and applied for these:
| Funding Opportunity |
|---|
| Nuclear Receptor Signaling Atlas (NURSA) Hub (U24) Apply for RFA DK 11 017 Funding Number: RFA DK 11 017 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Limited Competition for the Continuation of the Clinical Centers for The Environmental Determinants of Diabetes in the Young (TEDDY) Study (UC4) Apply for RFA DK 12 504 Funding Number: RFA DK 12 504 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Limited Competition for Continuation of the Prospective Study of Chronic Kidney Disease in Children (U01) Apply for RFA DK 12 507 Funding Number: RFA DK 12 507 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Mechanistic Insights from Birth Cohorts (R01) Apply for PAR 13 109 Funding Number: PAR 13 109 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: $500,000 |
| Home and Family Based Approaches for the Prevention or Management of Overweight or Obesity in Early Childhood (R01) Apply for PA 13 153 Funding Number: PA 13 153 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Home and Family Based Approaches for the Prevention or Management of Overweight or Obesity in Early Childhood (R21) Apply for PA 13 154 Funding Number: PA 13 154 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: $200,000 |
| Phenotyping Embryonic Lethal Knockout Mice (R01) Apply for PAR 13 231 Funding Number: PAR 13 231 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: $499,999 |
| Rare Diseases Clinical Research Consortia (RDCRC) for Rare Diseases Clinical Research Network (U54) Apply for RFA TR 13 002 Funding Number: RFA TR 13 002 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: $1,250,000 |
| Innovative Therapies and Tools for Screenable Disorders in Newborns (R01) Apply for PAR 14 270 Funding Number: PAR 14 270 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Understanding Factors in Infancy and Early Childhood (Birth to 24 months) That Influence Obesity Development (R01) Apply for PAR 14 323 Funding Number: PAR 14 323 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| New Technologies for Viral Hepatitis STTR (R41/R42) Apply for PA 15 076 Funding Number: PA 15 076 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| New Technologies for Viral Hepatitis SBIR (R43/R44) Apply for PA 15 077 Funding Number: PA 15 077 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Closed Loop Technologies Clinical and Behavioral Approaches to Improve Type 1 Diabetes Outcomes (R01) Apply for RFA DK 08 012 Funding Number: RFA DK 08 012 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: $500,000 |
| Closed Loop Technologies Pilot and Exploratory Clinical and Behavioral Approaches to Improve Type 1 Diabetes Outcomes (R21) Apply for RFA DK 08 013 Funding Number: RFA DK 08 013 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: $200,000 |
| Small Business Innovation Research to Develop New Therapeutics and Monitoring Technologies for Type 1 Diabetes (T1D). Towards an Artificial Pancreas (SBIR) R43/R44) Apply for RFA DK 09 001 Funding Number: RFA DK 09 001 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Type 1 Diabetes TrialNet Clinical Centers (U01) Apply for RFA DK 08 011 Funding Number: RFA DK 08 011 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Translational Research for the Prevention and Control of Diabetes and Obesity (R18) Apply for PAR 09 176 Funding Number: PAR 09 176 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: $500,000 |
| Planning Grants for Translational Research for the Prevention and Control of Diabetes and Obesity (R34) Apply for PAR 09 177 Funding Number: PAR 09 177 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: $300,000 |
| Basic and Clinical Studies of Congenital Urinary Tract Obstruction (R01) Apply for PA 09 226 Funding Number: PA 09 226 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Small Business Innovation Research to Develop New Therapeutics and Monitoring Technologies for Type 1 Diabetes (T1D). Towards an Artificial Pancreas (SBIR) (R43/R44) Apply for RFA DK 10 008 Funding Number: RFA DK 10 008 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DK 11 024", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.